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Abstract
Background/Aim. There is a high rate of schizophrenic pa-
tients who do not adhere to their prescribed therapy, despite
the implementation of antipsychotic long-acting injections
and the introduction of atypical antipsychotics.  The aim of
this study was to investigate the differences in sociodemo-
graphic, clinical and medication adherence variables between
the two groups of schizophrenic patients on maintenance
therapy with depot antipsychotic fluphenazine decanoate and
oral antipsychotics only as well as a correlation between the
medication adherence and other examined variables. Meth-
ods. A total of 56 patients of both genders, aged < 60 years,
with the diagnosis of schizophrenia (F20) (ICD-10, 1992)
clinically stable for at least 6 months were introduced in this
cross-sectional study. The patients from the depot group
(n = 19) were on classical depot antipsychotic fluphenazine
decanoate administering intramuscularly every 4 weeks (with
or without oral antipsychotic augmentation) and the patients
from the oral group (n = 37) were on oral therapy alone with
classical or atypical antipsychotics, either as monotherapy or
combined. The Positive and Negative Syndrome Scale
(PANSS) was used to assess symptom severity. Item G12 of
the PANSS was used to assess insight into the illness. The
patients completed the Medical Adherence Rating Scale
(MARS) was used to assess adherence to the therapy. A
higher MARS score indicates behavior [Medical Adherence
Questionnaire (MAQ subscale)] and attitudes toward medi-
cation [Drug Attitude Inventory (DAI subscale)] that are
more consistent with treatment adherence. The exclusion
criteria were determined. The Pearson's Ʒ2 test was used to
compare categorical variables, Student's t-test to compare
continuous variables and Pearson's correlation to test the cor-
relation significance; p = 0.05. Results. Significant between-
group differences in age, illness duration, chlorpromazine
equivalents, PANSS score and DAI subscore were found.
Item G12 of the PANSS subscore and MARS score corre-
lated significantly negatively. A significant positive correlation
between receiving depot antipsychotic and DAI subscore as
well as between illness duration and both DAI subscore and
MARS score were also found. Conclusion.  Schizophrenic
patients on classical depot antipsychotic maintenance therapy
might present subpopulation of patients with significantly
longer illness duration, more favorable medication attitude
and outcome in relation to those on oral antipsychotics alone.
Key words:
schizophrenia; therapeutics; pharmaceutical
preparations; antipsychotic agents; drug utilization;
delayed-action preparations.
Apstrakt
Uvod/Cilj. Postoji visoka stopa šizofrenih bolesnika koji se
ne pridržavaju propisane terapije uprkos primeni antipsiho-
tika u obliku injekcija dugog dejstva i uvoĀenja atipiÿnih an-
tipsihotika. Cilj ovog rada bio je da se ispitaju razlike u soci-
odemografskim, kliniÿkim i varijablama pridržavanja terapije
izmeĀu dve grupe šizofrenih bolesnika na terapiji održava-
nja depo antipsihotikom flufenazin-dekanoatom i samo
oralnim antipsihoticima, kao i da se utvrdi korelacija izmeĀu
pridržavanja terapije i drugih ispitivanih varijabli. Methode.
Ova studiju preseka obuhvatila je 56 bolesnika oba pola,
starosti < 60 godina sa dijagnozom šizofrenije (F20) (MKB-
10, 1992) koji su bili kliniÿki stabilni najmanje šest meseci.
Bolesnici depo grupe (n = 19) bili su na klasiÿnom depo an-
tipsihotiku flufenazin-dekanoatu koji se daje intramuskular-
no na ÿetiri nedelje (sa ili bez oralne augmentacije antipsi-
hoticima), a bolesnici oralne grupe (n = 37) bili su samo na
oralnoj terapiji klasiÿnim ili atipiÿnim antipsihotikom, bilo
kao monoterapija ili u kombinaciji. Skala pozitivnog i nega-
tivnog sindroma (PANSS) korišýena je za procenu težine
simptoma. Stavka G12 PANSS korišýena je za procenu uvi-
da u bolest. Skala procene pridržavanja leÿenja (MARS) koju
popunjava bolesnik, upotrebljena je za procenu pridržavanjaStrana 268 VOJNOSANITETSKI PREGLED Volumen 70, Broj 3
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terapije. Viši MARS skor ukazuje na ponašanje [Upitnik pri-
državanja leÿenja (MAQ subskala)] i stavove prema terapiji
[Inventar stavova prema terapiji (DAI supskala)] koji su više
u skladu sa pridržavanjem leÿenja. Kriterijumi iskljuÿivanja
bili su odreĀeni. Pearson-ov Ʒ2 test je korišýen za poreĀenje
kategorijskih varijabli, Student-ov t-test za poreĀenje konti-
nuiranih varijabli, a Pearson-ova korelacija je korišýena za
testiranje znaÿajnosti korelacije; p = 0,05. Rezultati. NaĀe-
ne su znaÿajne razlike izmeĀu grupa u starosti, dužini traja-
nja bolesti, ekvivalentima hlor-promazina, skoru PANSS i
supskoru DAI. Supskor G12 stavke PANSS i skor MARS
negativno su korelirali. TakoĀe, naĀena je i znaÿajna poziti-
vna korelacija izmeĀu primanja depo antipsihotika i supsko-
ra DAI, kao i izmeĀu dužine trajanja bolesti i supskora DAI
i skora MARS. Zakljuÿak. Šizofreni bolesnici na terapiji
održavanja klasiÿnim depo antipsihotikom mogu predstav-
ljati suppopulaciju bolesnika sa znaÿajno dužim trajanjem
bolesti, povoljnijim stavom prema leÿenju i ishodom u od-
nosu na one bolesnike koji su samo na oralnim antipsihoti-
cima.
Kljuÿne reÿi:
shizofrenija; leÿenje; lekovi; antipsihotici; lekovi,
korišýenje; lekovi, produženo dejstvo.
Introduction
In the treatment of schizophrenia, adherence is identi-
fied as the most important modifiable risk factor 
1. Non-
adherence patients have an average risk of relapse that is 3.7
times greater than that of good adherence patients 
2. Medica-
tion adherence behavior is a multifactorial phenomenon.
Meta-analytical studies 
3, 4 on risk factors for non-adherence
to medication in patients with schizophrenia showed a con-
sistent influence of certain variables (insight and therapeuti-
cal alliance, for example), while study results for other vari-
ables such as age, gender, marital status, duration of illness
are too inconsistent to let drawing a conclusion regarding
their influence on adherence behavior.
Depot formulations (long-acting injections) of classical
(first-generation) antipsychotics were introduced in the 1960s
to promote medication adherence. The use of classical depot
antipsychotics is less frequent
 in the last decade, perhaps owing
to the introduction
 of oral atypical antipsychotics. A prospec-
tive, observational study of the treatment for schizophrenia by
Shi et al.
5 found that only 26% of patients were treated with de-
pot formulations of typical antipsychotics at least once during
the designated three-year period. Clinicians use long-acting
 an-
tipsychotic injections to manage fewer than 1 in 5 patients
 with
schizophrenia having episodes of medication non-adherence 
6
despite treatment guidelines
 for schizophrenia recommend that
clinicians strongly consider
 depot therapy for patients who may
be non-adherent to antipsychotic
 treatment regimens 
7.
Depot antipsychotics
  are unable to prevent relapse
completely; even in clinical trials
 there are 20%–25% of pa-
tients who relapse,
 despite receiving depots. According to a
large, prospective, observational study of schizophrenia pa-
tients treated in ten European countries, the European
Schizophrenia Outpatient Health Outcomes (EU-SOHO), re-
ported that more than 50% of patients who were initiated on
classical depot antipsychotics or were switched to them were
treated with depot formulations to help address problems of
nonadherence, rather than for lack of efficacy or other rea-
sons 
8. Systematic literature reviews of randomized con-
trolled trials and observational studies of classical antipsy-
chotic long-acting injections vs. oral antipsychotics in
schizophrenia 
9, 10 suggested that classical depot antipsy-
chotics may improve outcome and significantly reduce re-
lapse rate compared with oral antipsychotics.
Over the past decade, a substantial number of patients
switched from classical depot antipsychotics to oral atypical
antipsychotics. However, one number of patients remains on
first- generation depot antipsychotic therapy long term.
The aim of this study was to investigate the differences
in sociodemographic, clinical and medication adherence
variables between the two groups of schizophrenic patients
on maintenance therapy with depot antipsychotic fluphen-
azine decanoate (group D) and oral antipsychotics only
(group O) as well as correlation between the medication ad-
herence and other examined variables.
Methods
A cross-sectional assessment of patients with schizo-
phrenia on maintenance treatment was undertaken.  The pa-
tients recruited for this study were regular on scheduled out-
patient visits for depot administration and/or prescription of
oral antipsychotic therapy and remained covered by the same
doses of antipsychotic drugs that had been applied at least 6
months before inclusion.
The inclusion criteria were that participants of both
genders were aged < 60 years, fulfilled International Statisti-
cal Classification
 of Diseases and Related Health Problems,
10th Revision 1992 (ICD; World Health Organization) 
11
criterion for schizophrenia (F 20), had been clinically stable
for 6 months, were currently prescribed either classical depot
antipsychotic therapy or oral antipsychotic therapy alone.
The sample consisted of 56 patients. The patients of the
depot group (the group D) (n = 19) were receiving fluphen-
azine decanoate administering intramuscularly every 4 weeks
with or without oral antipsychotic augmentation. The pa-
tients of the oral group (the group O) (n = 37) were using
antipsychotics either as monotherapy or in combination.
The patients were prescribed oral classical antipsy-
chotics (high potency-fluphenazine and low potency-
chlorpromazine or levomepromazine) and atypical antipsy-
chotics (risperidone and clozapine). Concomitant non-
antipsychotic psychotropic therapy was administered to the
patients included antidepressants or/and mood stabilizers to
attain better symptom control, as well as anticholinergics for
treating of extrapyramidal unwanted effects.
The dosage of each antipsychotic was converted to its
chlorpromazine equivalents 
12, 13.Volumen 70, Broj 3 VOJNOSANITETSKI PREGLED Strana 269
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Apart from the registration of both sociodemographic
and clinical data from medical records, the Positive and
Negative Syndrome Scale (PANSS) 
14 was performed to as-
sess symptom severity and the patients completing the Medi-
cal Adherence Rating Scale (MARS) 
15 was used to assess
adherence to medication.
The exclusion criteria were the following: a history of
drug abuse, evidence of organic brain disorder including
mental retardation, severe somatic disease.
Oral and written informed consent was obtained from
all participants prior to the participation in the study.
The study was conducted at the Outpatient’s Depart-
ment of Clinic for Psychiatry, Clinical Centre of Serbia, Bel-
grade, Serbia, from 2008 to February 2011.
Assessment
The PANSS 
14 is a 30-item (7 positive, 7 negative, and
16 general psychopathology symptom items) observer-rated
scale. Each item is rated on a severity scale ranging from 1
(absence of psychopathology) to 7 (extremely severe). A
possible range of scores on both Positive and Negative psy-
chopathology subscale is 7–49 and on General psychopa-
thology subscale is 16–112. Item G12 of the PANSS (higher
scores indicate worse insight into the illness) was used to as-
sess insight into the illness. Higher PANSS scores indicate
greater symptoms.
The MARS 
15 is patient completed scale. It contains 10
questions that require a Yes or No answer and indicates both
problematic behaviors with the questions from the Medical
Adherence Questionnaire (MAQ) 
16, a 4-item questionnaire
regarding ways in which patients may fail to take their pre-
scribed medication (forgetting, carelessness, stopping the drug
when they feel better, and stopping the drug because they be-
lieve in makes them feel worse), along with attitudes toward
medication, from 6 items based on the Drug Attitude Inven-
tory (DAI) 
17 regarding taking medication only when being
sick, being controlled by medication, clearer thoughts on
medication, prevention of getting sick by medication, feeling
weird, like a zombie on medication and feeling tired and slug-
gish on medication. The DAI provide rating of participants' at-
titude at the time of assessment; no time frame is specified in
the MAQ, which is a potential limitation of the measure.
Higher MARS scores indicate behavior and attitudes
that are more consistent with treatment adherence.
The Statistical Package for Social Science (SPSS) for
Windows,
 Version 13.0 was used for the analysis. Compari-
son of categorical variables of the two study groups was per-
formed using the Pearson's Ȥ
2 test and comparison of con-
tinuous variables was performed using the Student's t-test.
The Pearson’s correlation was used to test the correlation
significance. For all tests, a level of p = 0.05 (two-sided) was
considered significant.
Results
The sociodemographic and clinical characteristics of
the group D and the group O of patients are summarized in
Table 1. The patients of the group D were significantly older
and had significantly longer illness duration in comparison
with the patients of the group O.
Table 2 presents average doses of antipsychotic medi-
cations and mean chlorpromazine equivalent doses as well as
percentages of patients using concomitant psychotropic
medication in the groups D and O. Significantly lower doses
of clozapine were prescribed to the patients from the group D
and the patients from the same group were treated with sig-
nificantly higher antipsychotic doses in chlorpromazine
equivalents in relation to the patients from the group O. No
patient in the group D was treated with risperidone and halo-
peridol and t could not be computed.
Table 1 
Sociodemographic and clinical characteristics of schizophrenic outpatients
Variables Depot administration
(n = 19)
Oral administration
(n = 37)
Categorical variables n (%) n (%)
F
2 p
Gender
male 9 (47.3) 23 (62.2) 0.599 0.439
female 10 (52.7) 14 (37.8)
Marital status
married 2 (10.5) 3 (8.1) 1.077 0.584
single 15 (79.0) 26 (70.3)
divorced / widow 2 (10.5) 8 (21.6)
Live arrangement
alone 2 (10.5) 3 (8.1) 0.000 1.000
Work situation
working 6 (31.6) 8 (21.6) 0.239 0.625
Continuous variables ʉ SD ʉ SD tp
Age (yrs) 44.4 8.0 34.9 8.8 -3.892 0.000
Years of education 11.7 1.9 12.3 1.8 -1.068 0.290
Duration of treatment (yrs) 20.2 7.5 10.9 7.5 -4.335 0.000
n – number of patients, % – percentage of patients, ʉ – mean value, SD – standard deviationStrana 270 VOJNOSANITETSKI PREGLED Volumen 70, Broj 3
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The proportion of patients using anticholinergic drugs
was significantly higher in the group D of patients in relation
to the group O of patients.
The mean total PANSS, insight item G12 of the PANSS,
MARS as well as MAQ and DAI subscales of MARS scores
were shown in Table 3. Considerably lower mean total
PANSS score, Positive, Negative and General psychopathol-
ogy subscores in the group D of patients in comparison with
the group O of patients were found. The average DAI subscale
of MARS score was significantly higher in the group D of pa-
tients in relation to the group O of patients.
A significant negative correlation between item G12 of
the PANSS subscore and MARS score (r = -0.326, p =
0.014) was found. A significant positive correlation between
receiving depot therapy (the group D = 1, the group O = 0)
and DAI subscore (r = 0.364, p = 0.006), as well as between
illness duration and both DAI subscore (r = 0.483, p = 0.000)
and MARS score (r = 0.313, p = 0.019) were also found us-
ing the Pearson’s Correlation.
Discussion
According to the results obtained in this study, the
schizophrenic patients on typical depot antipsychotic main-
tenance treatment (the group D) had the following significant
differences in relation to the schizophrenic patients on oral
antipsychotics only (the group O): older age, longer illness
duration, lower symptom severity, higher antipsychotic doses
and more favorable attitude to treatment. A significant posi-
tive correlation between better insight and medication adher-
ence, between receiving depot treatment and attitude toward
medication and between illness duration and both attitude
toward medication and medication adherence (medium
strength of the relationships) were also found.
Fluphenazine decanoate, as maintenance treatment in
the group D of patients and haloperidol decanoate were the
most frequently used classical depot antipsychotics in the
previous decades in our environment, in addition to atypical
risperidone long-acting injection. Also, fluphenazine de-
canoate and haloperidol decanoate are still most available for
the greatest number of patients. Second-generation antipsy-
chotics prescription is most frequent in the last decade. For
these reasons, significantly older age and longer illness du-
ration of the group D of patients in comparison to the group
O of patients, could be expected results.
The majority of patients included in the study were
treated with more than one kind of antipsychotic drugs, in-
cluding concurrent use of oral and depot antipsychotics.
Table 2
Antipsychotic and concomitant medication of schizophrenic outpatients
Depot administration Oral administration
(n = 19) (n = 37) Variables Medication
n ʉ SD n ʉ SD
tp
Fluphenazine decanoate 19 25 mg /4w. 0 – – – – –
Fluphenazine   5 2.7 1.3 8 5.4 3.4 -1.693 0.069
Haloperidol – – – 6 6.8 4.4 – –
Chlorpromazine  5 82.4 37.1 4 100.0 35.3 -0.722 0.494
Levomepromazine  3 33.3 14.4 2 25.0 0.0 -0.775 0.495
Clozapine  3 75.0 0 17 189.7 128.7 -3.647 0.002
Risperidone – – – 8 3.3 1.3 – –
Continous
Chlorpromazine
equivalents   19 588 194 37 342 216 -4.145 0.000
 n (%) n (%) F
2 p
 Antidepressants  3 (15.7) 2  (5.4) 0.633 0.426
Mood stabilizers  5 (26.3) 2  (5.4) 3.289 0.070 Categorical
Anticholinergics  7 (36.8) 4 (10.8) 3.866 0.049
n – number of patients, % – percentage of patients, ʉ – mean dose of the medication (mg/day), SD – standard deviation
Table 3
Mean PANSS and MARS scores of schizophrenic outpatient
Psychometric scales
Depot administration
(n = 19)
Oral administration
(n = 37)
ʉ   SD ʉ SD
tp
PANSS
 a  70.0 14.1 84.6 19.9      2.846 0.006
POS
 b 12.4 3.3 15.2 5.4   2.048 0.045
NEG
 c 22.5 5.3 27.1 6.9   2.476 0.016
GEN
 d 34.9 6.7 42.2 10.2  2.790 0.007
G12 item
 e
MARS
 f
MAQ
 g
DAI
 h
2.7
8.5
3.0
5.2
1.1
1.4
0.7
0.7
3.2
7.7
2.8
4.2
1.3
2.4
1.1
1.3
 1.238
-1.612
 -0.611
-3.403
0.221
0.113
0.544
0.001
aThe Positive and Negative Syndrome Scale; 
bSubscale of positive symptoms  from the PANSS (higher scores indicate greater symptoms); 
cSubscale of negative
symptoms from the PANSS; 
dSubscale of general psychopatology from the PANSS;
 Item 
eG12 of the PANSS (insight into the illness)(higher scores indicate
worse insight into the illness); 
fThe Medical Adherence Rating Scale; 
gMedical Adherence Questionnaire; 
hDrug Attitude Inventory; ʉ  – mean score, SD –
standard deviationVolumen 70, Broj 3 VOJNOSANITETSKI PREGLED Strana 271
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Prolonged polypharmacy with antipsychotic drugs is preva-
lent in clinical practice 
18, 19 although, according to relevant
guidelines, it may be considered only in some cases of treat-
ment resistant patients 
20. However, it is believed that the use
of two or more antipsychotic drugs concomitantly (co-
prescribing) optimises symptom control, enables the reduc-
tion of positive as well as of negative symptoms and avoids
high doses of single drugs, thus reducing potential adverse
effects 
19.
The group D of patients had a
 significantly higher mean
chlorpromazine equivalent dose (588 +/- 194) than the group
O of patients (373 +/- 384) which is in accordance with the
findings from similar study 
21. Prescription of oral antipsy-
chotics (clozapine or low potency neuroleptics when neces-
sary) in the group D of patients influenced the results relating
to chlorpromazine equivalent doses in this study. One diffi-
culty in determining the lowest effective maintenance dose
for depot antipsychotics is the delay in relapse of symptoms
after a dosage reduction because a significant level of drug
remains in the tissues for weeks to months after drug discon-
tinuation 
22, 23.
Concomitant medication use in the patients included in
our study ranges from 11% to 37% for anticholinergics, 5%
to 16% for antidepressants and 5% to 26% for
mood stabilizers. Higher percentages of the patients from the
group D were treated with both antidepressants and mood
stabilizers in relation to the patients from the group O, but
the differences were not considerable. The frequency of anti-
cholinergic use as proxy indicator of extrapyramidal side-
effects was significantly higher in the group D of patients in
comparison with the group O of patients, possibly account-
ing for a significantly higher dose (chlorpromazine equiva-
lents) prescription in the D group in relation to the group O.
The results of Larsen and Gerlach's study 
24 regarding the at-
titude towards treatment, side-effects, mental state and qual-
ity of life of chronic schizophrenic out-patients on mainte-
nance treatment with depot neuroleptics showed that hypoki-
nesia and hyperkinesis were the adverse effects least noticed
by the patients, but most noticed by the treating physician,
while the opposite was the case with psychic side-effects
(dullness/tiredness). However, 88% of the patients included
in that study who reported no side-effects had at least one.
The neglect of this dimension may lead to non-compliance.
A consistent correlation between the presence or severity
 of
side-effects and the degree of adherence could not be found
in a systematic review 
25. Although intolerability
 is a major
cause of antipsychotic drug discontinuation in schizophrenia,
it often accounts for fewer discontinuations than the lack of
efficacy 
16.
 In a cross-sectional study
 of Patel et al. 
26 on ad-
herence to depot versus oral antipsychotic medication, be-
liefs and attitudes have been more important than side effects
in predicting self-reported adherence and influencing factors
thereof.
The findings of our study relating to psychopathology
(significantly lower symptom severity of total as well as
positive, negative and general psychopathology in the group
D of patients in regard to the group O of patients) suggested
a more favorable course of the illness of the group D of pa-
tients compared with the group O of patients. Several other
studies showed that antipsychotic drugs that are administered
in a depot injection
 are associated with lower rates of relapse
and hospital admission than medications
  that are adminis-
tered orally, because of the greater likelihood
 that the patient
will receive medication 
27. Meta-analytical study of David
and Adams 
28 showed that depot antipsychotic preparations
appear useful in relapse prevention when utilized for patients
with difficulties in medication compliance, despite limita-
tions of the analysis.  However, data is still limited in this
area.
The two groups of patients included in our study did
not differ in the level of insight into the illness that was de-
scribed as a strong predictor of adherence to medica-
tion 
4, 25, despite significant differences in symptoms sever-
ity. This result points out once again how much is difficult
to attain full insight into the disorder in patients with
schizophrenia irrespective illness duration, reduction of se-
verity of other symptoms and phase of treatment. However,
insight correlated significantly with medication adherence,
according to the results of our study. The group D of pa-
tients had better insight, but not significantly in relation to
the group O of patients and both patients groups had inter-
mediate level of insight. In considering these findings, we
should take into account the following: firstly, item G12 of
the PANSS (used in this study for assessment of insight
into the illness) addresses only to an improvement
 in under-
standing illness as well as medication consequences and
secondly, the patients included in the study were continu-
ously attending outpatient’s service for depot administra-
tion and/or prescription of oral antipsychotic therapy which
implies better insight into disorder in regard to those not
attending scheduled outpatients visits. We can speculate
that the majority of the participants
 on oral antipsychotics
were started and maintained on oral
 antipsychotics because
of their better insight and adherence.
 However, because of
the cross-sectional nature of the study
 design, it is not pos-
sible to ascertain the insight of the participants
 when they
were started on their medication.
 In addition, patient who
uses his/her medication
  because it improves well-being
does not necessarily need to
 have insight into the disorder.
This might explain why
 Nageotte et al. 
29 found that 38% of
patients were compliant
 despite the fact that they did not
believe themselves to be
  ill.
  Hogan et al.
17  demonstrated
that patients’
 experience of and adherence to antipsychotic
regimens depended
 on how they felt on medication, rather
than what they knew or
 believed about it.
Medication adherence was taken as continuous variable
in our study, having in mind that it is a dynamic phenomenon
and could change during a long-term treatment of schizo-
phrenia. The patients on depot antipsychotic therapy had sig-
nificantly better experience toward medication in comparison
with the patients on oral antipsychotic therapy in this study.
There are few data examining patient satisfaction or attitudes
regarding depot antipsychotics. The meta-analysis of Wal-
burrn et al.
30 showed that in 10 out of 12 studies, a positive
opinion towards
  depot antipsychotics was expressed. Five
out of six studies that
 compared depot with oral antipsychot-Strana 272 VOJNOSANITETSKI PREGLED Volumen 70, Broj 3
Stankoviý Ž, Ille T. Vojnosanit Pregl 2013; 70(3): 267–273.
ics showed patient preference
 for depots, although, patients
tended to state a preference
  for the formulation that they
were taking at the time. In a study by Patel et al.
31, the atti-
tudes regarding current formulation were influenced by ill-
ness duration, extrapyramidal symptoms and insight but not
by formulation (depot vs oral).
Despite considerably better medication attitude of the
group D of patients in relation to the group O of patients in
this study, the patients on depot therapy had less than a sig-
nificantly better medication-taking behavior and adherence
to the therapy in comparison with the patients on oral main-
tenance therapy. The patients from both study groups had
intermediate level of compliance with medication. The first
two questions of the MAQ subscale (assessing medication-
taking behavior) of MARS related to unintentional non-
compliance, regarding forgetfulness and carelessness (often
confusing for patients) might influence the results of the
study referring to compliance behavior. However, there are
findings showing the lack of correlation between medication
attitudes and medication-taking behavior of the patients 
32 as
well as that patient’s attitudes to medication may be com-
pletely different from their actual medication-taking behav-
ior 
33. Having in mind the frequent need for concurrent pre-
scribing of oral medication in patients with schizophrenia on
depot antipsychotic therapy, findings regarding medication-
taking behavior seem to be important not only for patients on
oral therapy alone, but also for the patients receiving depot
maintenance therapy.
The findings from this study relating to medication ad-
herence in the patients with schizophrenia on maintenance
treatment, obtained by examination of certain variables,
show the complexity of this issue. Compliance behavior re-
mains problematic in both the patients receiving classical de-
pot antipsychotics and those using oral antipsychotics only.
They are needed prospective longitudinal studies on medica-
tion adherence in patients with schizophrenia on depot anti-
psychotics, from the introduction of depot therapy and the
course of the treatment process.
There are several limitations of the present study which
included a heterogeneous sample of 56 participants. This
number is relatively low (particularly in the group D as a re-
flection of the lower frequency of the use of classical depot
antipsychotics) for analysis of between-group differences.
However, between-group differences in some variables
which were examined in this study were significant even
with this low numbers
 per group.
The patients included in this study had to be clinically
stable
 for at least six months and to regularly attend outpa-
tient’s service before inclusion. These inclusion criteria
probably influenced our results because these patients
 maybe
stressed the importance of factors that positively
 influenced
medication adherence, but data of non-attendee’s and non-
compliers were hard to obtain.
Both patients groups were mixed regarding the type
of antipsychotics which were prescribed (both atypical and
typical antipsychotics were prescribed either as monother-
apy or in combination in the group O of patients and clo-
zapine or low-potency antipsychotics in one number of
patients in the group D). That probably influenced the
finding addressing medication attitude, having in mind dif-
ferent profile of adverse effect of typical vs atypical anti-
psychotics.
The group D included the patients with additional oral
medication (antipsychotics or/and concomitant non-
antipsychotic psychotropic drugs). For these reasons, a sig-
nificantly better medication attitude of the group D compared
to the group O could not address to depot therapy in particu-
lar. Further, the group O included the patients who had been
either on depot in the past or at least offered them. The views
of such patients on depot medication would complete the
picture.
Future investigations designed as prospective clinical
studies, with larger sample including patients covered by an-
tipsychotic depot monotherapy and subject groups matched
by sociodemographic and clinical characteristics could de-
crease limitations of our study.
Conclusion
In comparison with schizophrenic patients on oral
maintenance therapy alone, patients on classical depot anti-
psychotic maintenance treatment were significantly older,
had longer illness duration, were treated with higher anti-
psychotic chlorpromazine equivalents doses, had more of-
ten prescribed anticholinergics, had lower severity of psy-
chopathology and more favorable attitude toward medica-
tion.
Insight into the disorder and medication adherence,
treatment with typical depot antipsychotics and attitude to
medication as well as illness duration and both medication
adherence and attitude to treatment were significantly corre-
lated.
This study was completed with the idea of applicability
in everyday clinical practice, given that classical depot anti-
psychotics are still frequently used in a population of schizo-
phrenic patients on maintenance therapy in Serbia.
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